{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "e447e2d6",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/opt/homebrew/anaconda3/envs/birdhouse_backend_env/lib/python3.12/site-packages/tqdm/auto.py:21: TqdmWarning: IProgress not found. Please update jupyter and ipywidgets. See https://ipywidgets.readthedocs.io/en/stable/user_install.html\n",
      "  from .autonotebook import tqdm as notebook_tqdm\n"
     ]
    }
   ],
   "source": [
    "from pydantic import BaseModel, Field\n",
    "import json\n",
    "from pathlib import Path\n",
    "\n",
    "from dotenv import load_dotenv\n",
    "import dspy"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "e22f0e40",
   "metadata": {},
   "outputs": [],
   "source": [
    "SIMULATED_BACKEND_PATH = \"simulated_backend/\"\n",
    "\n",
    "output_dir = Path(SIMULATED_BACKEND_PATH) / \"generated_documents\"\n",
    "output_dir.mkdir(exist_ok=True, parents=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "e7ee977d",
   "metadata": {},
   "outputs": [],
   "source": [
    "load_dotenv(\"../.env\")\n",
    "lm = dspy.LM(\"gemini/gemini-2.5-pro\", temperature=0.5, cache=True, max_tokens=25000)\n",
    "dspy.settings.configure(lm=lm, track_usage=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "7f76badb",
   "metadata": {},
   "outputs": [],
   "source": [
    "ORG_NAME = \"Denali Therapeutics\"\n",
    "ORG_TYPE = \"Sponsor\"\n",
    "\n",
    "STAFF_NAME = \"Alex Johnson\"\n",
    "STAFF_TYPE = \"Clinical Research Coordinator\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "1302ee7f",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Given the name and type (sponsor, CRO, or site organization) of the organization running clinical research below, do research and think hard to give information about the organization and their clinical research that might be relevant to their clinical research operations. \n",
      "\n",
      "Describe\n",
      "- therapeutic focus (or the many)\n",
      "- any ongoing clinical trials\n",
      "- location of the clinical research (or many cites/countries)\n",
      "- other information relevant to their clinical trial operations\n",
      "\n",
      "Give a concise but complete bullet point for each of these.\n",
      "\n",
      "Organization Name: Denali Therapeutics\n",
      "Organization Type: Sponsor\n"
     ]
    }
   ],
   "source": [
    "# Enter into ChatGPT\n",
    "\n",
    "ORG_INFO_PROMPT = f\"\"\"Given the name and type (sponsor, CRO, or site organization) of the organization running clinical research below, do research and think hard to give information about the organization and their clinical research that might be relevant to their clinical research operations. \n",
    "\n",
    "Describe\n",
    "- therapeutic focus (or the many)\n",
    "- any ongoing clinical trials\n",
    "- location of the clinical research (or many cites/countries)\n",
    "- other information relevant to their clinical trial operations\n",
    "\n",
    "Give a concise but complete bullet point for each of these.\n",
    "\n",
    "Organization Name: {ORG_NAME}\n",
    "Organization Type: {ORG_TYPE}\"\"\"\n",
    "\n",
    "print(ORG_INFO_PROMPT)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "af62e476",
   "metadata": {},
   "outputs": [],
   "source": [
    "ORG_INFORMATION = \"\"\"\n",
    "- Therapeutic focus: Biotech focused on neurodegenerative and lysosomal storage diseases, especially disorders with high unmet need like Parkinson’s, Alzheimer’s, ALS, frontotemporal dementia (FTD-GRN), Hunter syndrome (MPS II), and Sanfilippo syndrome (MPS IIIA), using its blood–brain barrier “TransportVehicle™” platform for antibodies, enzymes and oligonucleotides to deliver drugs into the CNS.  ￼\n",
    "- Ongoing clinical trials: Key active programs include: tividenofusp alfa (DNL310) for Hunter syndrome, with a Phase 1/2 dataset supporting an FDA BLA under priority review and long-term extension studies; DNL126 for MPS IIIA in a Phase 1 pediatric trial; BIIB122/DNL151 (with Biogen) in Phase 2b LUMA and Phase 3 LIGHTHOUSE studies for Parkinson’s disease; TAK-594/DNL593 (with Takeda) for FTD-GRN; DNL919 for Alzheimer’s disease; and DNL343 for ALS, which showed a negative 6-month efficacy readout but remained safe and is still under further data analysis.  ￼\n",
    "- Clinical trial geographies & sites: Headquarters is in South San Francisco, with a new biologics manufacturing and development facility in Salt Lake City, Utah; interventional trials are run across multi-center networks, including dozens of sites in the United States (e.g., California, Wisconsin) plus additional locations in Europe and other regions through EU-registered trials and global genetics/observational studies (e.g., ROPAD Parkinson’s genetics study at ~48 sites worldwide that can funnel into Denali interventional trials).  ￼\n",
    "- Other clinical-operations-relevant details: Clinical development is tightly coupled to Denali’s BBB-crossing platform (Antibody and Oligonucleotide Transport Vehicles) and run in partnership with large pharmas (Biogen for BIIB122/DNL151, Takeda for TAK-594/DNL593, Sanofi for SAR443122/DNL758 in ulcerative colitis), supported by strong financing with cash runway projected into 2028; they also run grants/sponsorships and patient-advocacy programs and maintain an in-house clinical trials contact group (clinical-trials@dnli.com) to coordinate multi-site studies.  ￼\n",
    "\"\"\"\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "20ca0170",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{'id': 'doc_001',\n",
       "  'name': 'Protocol_BIIB122-DNL151_LIGHTHOUSE_Amendment_v4.0.pdf',\n",
       "  'description': \"Amendment 4 to the Phase 3 LIGHTHOUSE study protocol for Parkinson's disease. This version incorporates updated guidance on CSF biomarker sample collection and adjusts the statistical analysis plan based on recommendations from the Data Monitoring Committee.\",\n",
       "  'modified': '2024-05-15T14:30:00Z',\n",
       "  'version': '4.0',\n",
       "  'type': 'pdf'},\n",
       " {'id': 'doc_002',\n",
       "  'name': 'DNL310_Investigator_Brochure_Ed9_2024.pdf',\n",
       "  'description': \"9th Edition of the Investigator's Brochure for tividenofusp alfa (DNL310), summarizing all current non-clinical and clinical data, including pharmacology, toxicology, and integrated safety information from the Phase 1/2 study and long-term extension in patients with Hunter Syndrome (MPS II).\",\n",
       "  'modified': '2024-04-22T11:00:00Z',\n",
       "  'version': '9.0',\n",
       "  'type': 'pdf'},\n",
       " {'id': 'doc_003',\n",
       "  'name': 'CSR_DNL310-001_Final_Report.docx',\n",
       "  'description': 'Final Clinical Study Report for study DNL310-001, a Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of tividenofusp alfa in patients with Hunter syndrome. This report forms a core component of the BLA submission.',\n",
       "  'modified': '2024-02-10T18:45:00Z',\n",
       "  'version': '1.0 Final',\n",
       "  'type': 'docx'},\n",
       " {'id': 'doc_004',\n",
       "  'name': 'Master_ICF_Template_DNL126-001_Pediatric_v2.1.docx',\n",
       "  'description': 'Master Informed Consent Form (ICF) and Assent Form template for study DNL126-001 in pediatric patients with Sanfilippo syndrome (MPS IIIA). Version 2.1 includes updated language on genetic data privacy and long-term follow-up procedures.',\n",
       "  'modified': '2024-06-05T09:12:00Z',\n",
       "  'version': '2.1',\n",
       "  'type': 'docx'},\n",
       " {'id': 'doc_005',\n",
       "  'name': 'DSUR_DNL343-ALS_Annual_Report_2023.pdf',\n",
       "  'description': 'Annual Development Safety Update Report (DSUR) for the DNL343 program in ALS. This report provides a comprehensive analysis of safety data from the reporting period, including an evaluation of the negative efficacy readout and ongoing safety monitoring.',\n",
       "  'modified': '2024-03-28T16:20:00Z',\n",
       "  'version': '2023.v1',\n",
       "  'type': 'pdf'},\n",
       " {'id': 'doc_006',\n",
       "  'name': 'Denali-Takeda_JSC_Meeting_Minutes_Q1_2024.pdf',\n",
       "  'description': 'Meeting minutes from the Q1 2024 Joint Steering Committee (JSC) for the TAK-594/DNL593 collaboration. Key discussion points include enrollment progress for the FTD-GRN study, review of preclinical data, and alignment on regulatory strategy.',\n",
       "  'modified': '2024-04-18T10:05:00Z',\n",
       "  'version': '1.0',\n",
       "  'type': 'pdf'},\n",
       " {'id': 'doc_007',\n",
       "  'name': 'DNL919-AD_SIV_Presentation_Template_US_v1.2.pptx',\n",
       "  'description': \"Site Initiation Visit (SIV) presentation template for US sites participating in the Phase 1b study of DNL919 in Alzheimer's disease. This deck provides investigators and site staff with a comprehensive overview of the protocol, study procedures, and use of the Transport Vehicle platform.\",\n",
       "  'modified': '2024-05-29T13:00:00Z',\n",
       "  'version': '1.2',\n",
       "  'type': 'pptx'},\n",
       " {'id': 'doc_008',\n",
       "  'name': 'BLA_21XXXX_DNL310_Module_3_CMC_Overview.pdf',\n",
       "  'description': 'CTD Module 3 (Quality) overview for the Biologics License Application (BLA) for tividenofusp alfa (DNL310). This document details the Chemistry, Manufacturing, and Controls (CMC) for the drug substance and product, including information from the Salt Lake City facility.',\n",
       "  'modified': '2024-01-15T20:00:00Z',\n",
       "  'version': '1.0',\n",
       "  'type': 'pdf'},\n",
       " {'id': 'doc_009',\n",
       "  'name': 'ROPAD_Study_Site_Newsletter_Q2_2024.pdf',\n",
       "  'description': \"Quarterly newsletter for the ~48 global sites participating in the ROPAD Parkinson's genetics and observational study. This issue highlights enrollment milestones and provides an update on how ROPAD data is helping to identify candidates for Denali's interventional trials.\",\n",
       "  'modified': '2024-06-12T15:00:00Z',\n",
       "  'version': 'Q2 2024',\n",
       "  'type': 'pdf'},\n",
       " {'id': 'doc_010',\n",
       "  'name': 'Patient_Advocacy_Communication_DNL310_BLA_Update.pdf',\n",
       "  'description': \"A communication document for patient advocacy groups and the broader Hunter syndrome community, providing an update on the FDA's acceptance of the BLA for tividenofusp alfa (DNL310) under Priority Review and outlining anticipated timelines.\",\n",
       "  'modified': '2024-03-04T12:30:00Z',\n",
       "  'version': '1.0',\n",
       "  'type': 'pdf'}]"
      ]
     },
     "execution_count": 8,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "class Document(BaseModel):\n",
    "    \"\"\"A document relevant to clinical trial operations.\n",
    "\n",
    "    Fields:\n",
    "    - id: Unique identifier for the document (e.g., doc_001)\n",
    "    - name: Filename of the document (e.g., Protocol_DNLI-001_Amendment_v3.2.pdf)\n",
    "    - description: Brief description of the document's content and purpose\n",
    "    - modified: Date when the document was last modified (ISO 8601 format)\n",
    "    - version: Version number of the document\n",
    "    - type: File type/extension (e.g., pdf, docx)\n",
    "    \"\"\"\n",
    "\n",
    "    id: str\n",
    "    name: str\n",
    "    description: str\n",
    "    modified: str\n",
    "    version: str\n",
    "    type: str\n",
    "\n",
    "\n",
    "class GenerateOrgDocuments(dspy.Signature):\n",
    "    \"\"\"Generate a list of documents that might be relevant to the operations of a company running clinical trials.\n",
    "\n",
    "    Based on the organization's information, create realistic documents such as protocols, amendments, safety reports, etc.\n",
    "    Vary the types of documents to cover different aspects of clinical trial operations.\n",
    "    \"\"\"\n",
    "\n",
    "    org_name: str = dspy.InputField(desc=\"Name of the organization running clinical trials\")\n",
    "    org_type: str = dspy.InputField(\n",
    "        desc=\"Type of the organization (e.g., Sponsor, CRO, Site Organization)\"\n",
    "    )\n",
    "    org_information: str = dspy.InputField(\n",
    "        desc=\"Detailed information about the organization running clinical trials\"\n",
    "    )\n",
    "    num_documents: int = dspy.InputField(desc=\"Number of documents to generate\")\n",
    "\n",
    "    documents: list[Document] = dspy.OutputField(\n",
    "        desc=\"List of relevant documents for the organization's operations\"\n",
    "    )\n",
    "\n",
    "\n",
    "documents_predict = dspy.Predict(GenerateOrgDocuments)\n",
    "documents = documents_predict(\n",
    "    org_name=ORG_NAME,\n",
    "    org_type=ORG_TYPE,\n",
    "    org_information=ORG_INFORMATION,\n",
    "    num_documents=10,\n",
    ").documents\n",
    "\n",
    "documents_data = [doc.model_dump() for doc in documents]\n",
    "\n",
    "with open(output_dir / \"docs_info.json\", \"w\") as f:\n",
    "    json.dump(documents_data, f, indent=2)\n",
    "\n",
    "documents_data"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "ab4ab0e7",
   "metadata": {},
   "outputs": [],
   "source": [
    "class DraftSyntheticEmailDescription(dspy.Signature):\n",
    "    \"\"\"Given a ClinicalTrials.gov study ID and a role (eg CRA, CTM), create descriptions of email threads that the person with the role (at the sponsor level) would be expected to be help resolve.\n",
    "    Vary the email threads to cover different types of common clinical trial communications (eg SAE reporting, monitoring visit scheduling, data queries, protocol deviations, etc).\n",
    "    Vary the urgency of the email threads (eg routine, urgent, critical).\n",
    "    Vary the complexity of the email threads (eg single email, multi-email back and forth).\n",
    "    Vary the source of the email thread (site to sponsor, CRO to sponsor, sponsor to site, etc).\n",
    "\n",
    "    Ex for a CRA, make one email thread about scheduling a monitoring visit, one about following up on overdue data queries, one about reporting an SAE, etc.\n",
    "    \"\"\"\n",
    "\n",
    "    study_overview: str = dspy.InputField(desc=\"The ClinicalTrials.gov study overview\")\n",
    "    name: str = dspy.InputField(\n",
    "        desc=\"The name of the person who would be expected to take action in response to the email thread\"\n",
    "    )\n",
    "    role: str = dspy.InputField(\n",
    "        desc=\"The role of the person who would be expected to take action in response to the email thread\"\n",
    "    )\n",
    "    organization: str = dspy.InputField(\n",
    "        desc=\"The organization of the person with the given role (eg sponsor, CRO, site)\"\n",
    "    )\n",
    "    num_threads: int = dspy.InputField(\n",
    "        desc=\"The number of email threads to create descriptions for\"\n",
    "    )\n",
    "\n",
    "    # Outputs\n",
    "    email_descriptions: list[str] = dspy.OutputField(\n",
    "        desc=\"A list of descriptions of the email threads that the role would be expected to help resolve. Don't number threads.\"\n",
    "    )\n",
    "\n",
    "\n",
    "class Email(BaseModel):\n",
    "    \"\"\"An email message including metadata for clinical trial communications.\n",
    "\n",
    "    Metadata fields:\n",
    "    - from_address: Email address of the sender (e.g., site coordinator, CRA, medical monitor)\n",
    "    - to_addresses: List of primary recipient email addresses who need to take action\n",
    "    - cc_addresses: List of email addresses copied for awareness (e.g., project managers, medical monitors)\n",
    "    - subject: Email subject line, often includes study ID, urgency indicators, and topic\n",
    "    - timestamp: ISO 8601 formatted timestamp indicating when the email was sent\n",
    "    - body: Full text content of the email message, including greetings, content, and signature\n",
    "    - attachments: List of attachment filenames (e.g., SAE forms, source documents, meeting agendas)\n",
    "    - message_id: Unique identifier for the email message in the thread\n",
    "    - in_reply_to: Message ID of the email being replied to, or None if this starts a new thread\n",
    "    \"\"\"\n",
    "\n",
    "    from_address: str\n",
    "    to_addresses: list[str]\n",
    "    cc_addresses: list[str]\n",
    "    subject: str\n",
    "    timestamp: str\n",
    "    body: str\n",
    "    attachments: list[str]\n",
    "    message_id: int\n",
    "    in_reply_to: int | None\n",
    "\n",
    "\n",
    "class DraftSyntheticEmailThread(dspy.Signature):\n",
    "    \"\"\"Given a description of an email thread and a role of a person to include, draft a synthetic email thread that includes the person with the given role (this person is always at the sponsor organization).\n",
    "    Come up with names for organizations (sponsor, CRO, site) people, attachments in the email thread as needed to make the email thread realistic.\n",
    "    The email thread should include realistic email metadata (from, to, cc, subject, timestamp, attachments, message IDs, in-reply-to fields).\n",
    "    The email thread should end before the specified person takes action (reply to email, redirect email, confirm follow up, schedule meeting, etc), such that the next reply would be from this person.\n",
    "    \"\"\"\n",
    "\n",
    "    email_description: str = dspy.InputField(desc=\"The description of the email thread to draft\")\n",
    "    name: str = dspy.InputField(\n",
    "        desc=\"The name of the person (at the sponsor level) that must take action (reply to email, redirect email, confirm follow up, schedule meeting, etc) in the email thread.\"\n",
    "    )\n",
    "    role: str = dspy.InputField(\n",
    "        desc=\"The role of the person (at the sponsor level) that must take action (reply to email, redirect email, confirm follow up, schedule meeting, etc) in the email thread. This person is always at the sponsor organization.\"\n",
    "    )\n",
    "    organization: str = dspy.InputField(\n",
    "        desc=\"The organization of the person with the given role (eg sponsor, CRO, site) that must take action in the email thread.\"\n",
    "    )\n",
    "\n",
    "    email_thread: list[Email] = dspy.OutputField(desc=\"The synthetic email thread\")\n",
    "    role_descriptions: list[str] = dspy.OutputField(\n",
    "        desc=\"\"\"Map of \"email addresses: organization, role\" in the email thread. \n",
    "        Organization can be sponsor, CRO or site. \n",
    "        Given role is always at sponsor organization and must be included in mapping.\n",
    "        Ex: jane.doe@denalitx.com: Denali Therapeutics (Sponsor), Clinical Research Associate\"\"\"\n",
    "    )"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "2d88fe80",
   "metadata": {},
   "outputs": [],
   "source": [
    "STUDY_OVERVIEW = \"\"\"\n",
    "            Brief Summary\n",
    "\n",
    "            This is a Phase 1/2, multicenter, randomized, placebo-controlled, double-blind study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of DNL593 in two parts followed by an optional open-label extension (OLE) period.\n",
    "\n",
    "            Part A will evaluate the safety, tolerability, PK, and PD of single doses of DNL593 in healthy male and healthy female participants of nonchildbearing potential. Part B will evaluate the safety, tolerability, PK, and PD of multiple doses of DNL593 in participants with frontotemporal dementia (FTD) over 25 weeks. Part B will be followed by Part C, an optional 18-month OLE period available for all participants who complete Part B.\n",
    "            Official Title\n",
    "            A Phase 1/2, Multicenter, Randomized, Placebo-Controlled, Double Blind Single Dose and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia Followed by an Open-Label Extension\n",
    "            Conditions\n",
    "            Frontotemporal Dementia\n",
    "            Intervention / Treatment\n",
    "\n",
    "                Drug: DNL593\n",
    "                Drug: Placebo\n",
    "\n",
    "            Sponsor: Denali Therapeutics\n",
    "          \"\"\"\n",
    "\n",
    "NAME = \"Alex Johnson\"\n",
    "\n",
    "ROLE = \"Clinical Research Associate\"\n",
    "\n",
    "ORGANIZATION = \"Denali Therapeutics (Sponsor)\"\n",
    "\n",
    "NUM_THREADS = 10"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "11607d53",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['An urgent email thread initiated by a site coordinator at UCLA reporting a Serious Adverse Event (SAE) for a patient in Part B. The patient was hospitalized for pneumonia. The thread involves Alex Johnson acknowledging the report, requesting source documents, and confirming the 24-hour reporting timeline with the Denali safety team.',\n",
       " \"A routine scheduling back-and-forth between Alex Johnson and a clinical research coordinator at a study site to finalize dates for the next quarterly Interim Monitoring Visit (IMV). The thread includes proposed dates from Alex, a counter-proposal from the site due to the Principal Investigator's vacation, and a final confirmation.\",\n",
       " \"An email from Alex Johnson to a low-performing site's research team following up on a list of over 30 data queries that have been outstanding for more than 14 days. The email serves as a formal reminder and requests an estimated timeline for resolution to ensure the database lock for Part A is not delayed.\",\n",
       " \"A multi-part discussion with a Principal Investigator who reported a protocol deviation where a participant in the FTD cohort (Part B) was accidentally administered a double dose of the investigational product. The thread involves Alex Johnson escalating the issue to the study's medical monitor for guidance on patient safety and follow-up procedures.\",\n",
       " \"An urgent notification from a site pharmacist regarding a temperature excursion in the refrigerator storing the DNL593 and placebo. The thread shows Alex Johnson coordinating with Denali's clinical supply manager to determine if the product is still viable and providing instructions to the site to quarantine the affected stock.\",\n",
       " 'A routine follow-up email from Alex Johnson to a site coordinator regarding outstanding action items from the last monitoring visit report. The email specifically requests an updated Delegation of Authority Log to reflect a new sub-investigator and confirmation of completed training for the new staff member.',\n",
       " 'An inquiry from a site coordinator asking for clarification on the screening procedures for healthy volunteers in Part A, specifically regarding the exclusion criteria related to liver function tests. Alex Johnson provides a clear answer by referencing the specific section of the protocol.',\n",
       " 'A thread initiated by Alex Johnson to a site that has not yet screened any patients for the FTD cohort (Part B). The email is a proactive check-in to discuss potential recruitment barriers and offer support, such as reviewing their pre-screening strategies or providing new recruitment materials.',\n",
       " \"A request from Denali's internal TMF specialist to Alex Johnson asking for the IRB approval letter for a recently submitted protocol amendment from a central site. Alex needs to locate the document and ensure it is uploaded to the eTMF system correctly.\",\n",
       " 'A back-and-forth conversation with a site regarding a participant in Part B who is nearing the end of the 25-week treatment period and has questions about rolling over into the Open-Label Extension (Part C). The site is asking for clarification on the visit schedule and procedures in the OLE to properly consent the participant.']"
      ]
     },
     "execution_count": 5,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "email_descriptions_predict = dspy.Predict(DraftSyntheticEmailDescription)\n",
    "email_descriptions = email_descriptions_predict(\n",
    "    study_overview=STUDY_OVERVIEW,\n",
    "    name=NAME,\n",
    "    role=ROLE,\n",
    "    organization=ORGANIZATION,\n",
    "    num_threads=NUM_THREADS,\n",
    ").email_descriptions\n",
    "\n",
    "email_descriptions"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "5aadc263",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Generating email thread for description:  An urgent email thread initiated by a site coordinator at UCLA reporting a Serious Adverse Event (SAE) for a patient in Part B. The patient was hospitalized for pneumonia. The thread involves Alex Johnson acknowledging the report, requesting source documents, and confirming the 24-hour reporting timeline with the Denali safety team.\n",
      "Saved thread 0 to generated_email_threads_2/thread_000.json\n",
      "Generating email thread for description:  A routine scheduling back-and-forth between Alex Johnson and a clinical research coordinator at a study site to finalize dates for the next quarterly Interim Monitoring Visit (IMV). The thread includes proposed dates from Alex, a counter-proposal from the site due to the Principal Investigator's vacation, and a final confirmation.\n",
      "Saved thread 1 to generated_email_threads_2/thread_001.json\n",
      "Generating email thread for description:  An email from Alex Johnson to a low-performing site's research team following up on a list of over 30 data queries that have been outstanding for more than 14 days. The email serves as a formal reminder and requests an estimated timeline for resolution to ensure the database lock for Part A is not delayed.\n",
      "Saved thread 2 to generated_email_threads_2/thread_002.json\n",
      "Generating email thread for description:  A multi-part discussion with a Principal Investigator who reported a protocol deviation where a participant in the FTD cohort (Part B) was accidentally administered a double dose of the investigational product. The thread involves Alex Johnson escalating the issue to the study's medical monitor for guidance on patient safety and follow-up procedures.\n",
      "Saved thread 3 to generated_email_threads_2/thread_003.json\n",
      "Generating email thread for description:  An urgent notification from a site pharmacist regarding a temperature excursion in the refrigerator storing the DNL593 and placebo. The thread shows Alex Johnson coordinating with Denali's clinical supply manager to determine if the product is still viable and providing instructions to the site to quarantine the affected stock.\n",
      "Saved thread 4 to generated_email_threads_2/thread_004.json\n",
      "Generating email thread for description:  A routine follow-up email from Alex Johnson to a site coordinator regarding outstanding action items from the last monitoring visit report. The email specifically requests an updated Delegation of Authority Log to reflect a new sub-investigator and confirmation of completed training for the new staff member.\n",
      "Saved thread 5 to generated_email_threads_2/thread_005.json\n",
      "Generating email thread for description:  An inquiry from a site coordinator asking for clarification on the screening procedures for healthy volunteers in Part A, specifically regarding the exclusion criteria related to liver function tests. Alex Johnson provides a clear answer by referencing the specific section of the protocol.\n",
      "Saved thread 6 to generated_email_threads_2/thread_006.json\n",
      "Generating email thread for description:  A thread initiated by Alex Johnson to a site that has not yet screened any patients for the FTD cohort (Part B). The email is a proactive check-in to discuss potential recruitment barriers and offer support, such as reviewing their pre-screening strategies or providing new recruitment materials.\n",
      "Saved thread 7 to generated_email_threads_2/thread_007.json\n",
      "Generating email thread for description:  A request from Denali's internal TMF specialist to Alex Johnson asking for the IRB approval letter for a recently submitted protocol amendment from a central site. Alex needs to locate the document and ensure it is uploaded to the eTMF system correctly.\n",
      "Saved thread 8 to generated_email_threads_2/thread_008.json\n",
      "Generating email thread for description:  A back-and-forth conversation with a site regarding a participant in Part B who is nearing the end of the 25-week treatment period and has questions about rolling over into the Open-Label Extension (Part C). The site is asking for clarification on the visit schedule and procedures in the OLE to properly consent the participant.\n",
      "Saved thread 9 to generated_email_threads_2/thread_009.json\n",
      "Saved summary to generated_email_threads_2/all_threads.json\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "{'emails': [{'from_address': 'schen@ucsfmed.org',\n",
       "   'to_addresses': ['david.miller@syneos.com'],\n",
       "   'cc_addresses': ['mlee@ucsfmed.org'],\n",
       "   'subject': '[DNLI-001] Site 101 - Participant 101-005 - OLE Rollover Query',\n",
       "   'timestamp': '2023-10-26T10:15:00Z',\n",
       "   'body': 'Hi David,\\n\\nHope you are well.\\n\\nWe have a query regarding participant 101-005. The participant is approaching their Week 25 visit and has expressed strong interest in continuing into the Open-Label Extension (Part C) of the study.\\n\\nTo ensure we can properly consent them, could you please provide clarification on the visit schedule and any specific procedures required for the OLE portion of the trial? We want to make sure we have all the correct information to discuss with the participant.\\n\\nPlease let us know.\\n\\nBest regards,\\n\\nSarah Chen\\nClinical Research Coordinator\\nUCSF Medical Center',\n",
       "   'attachments': [],\n",
       "   'message_id': 1,\n",
       "   'in_reply_to': None},\n",
       "  {'from_address': 'david.miller@syneos.com',\n",
       "   'to_addresses': ['alex.johnson@denalitx.com'],\n",
       "   'cc_addresses': ['maria.garcia@denalitx.com'],\n",
       "   'subject': 'Fwd: [DNLI-001] Site 101 - Participant 101-005 - OLE Rollover Query',\n",
       "   'timestamp': '2023-10-26T11:30:00Z',\n",
       "   'body': 'Hi Alex,\\n\\nPlease see the query below from Site 101 regarding the OLE rollover for participant 101-005.\\n\\nCould you please provide the site with the requested clarification on the visit schedule and procedures for Part C?\\n\\nThanks,\\nDavid\\n\\n--- Forwarded message ---\\nFrom: Sarah Chen <schen@ucsfmed.org>\\nDate: Thu, Oct 26, 2023 at 10:15 AM\\nSubject: [DNLI-001] Site 101 - Participant 101-005 - OLE Rollover Query\\nTo: David Miller <david.miller@syneos.com>\\nCc: Michael Lee <mlee@ucsfmed.org>\\n\\nHi David,\\n\\nHope you are well.\\n\\nWe have a query regarding participant 101-005. The participant is approaching their Week 25 visit and has expressed strong interest in continuing into the Open-Label Extension (Part C) of the study.\\n\\nTo ensure we can properly consent them, could you please provide clarification on the visit schedule and any specific procedures required for the OLE portion of the trial? We want to make sure we have all the correct information to discuss with the participant.\\n\\nPlease let us know.\\n\\nBest regards,\\n\\nSarah Chen\\nClinical Research Coordinator\\nUCSF Medical Center',\n",
       "   'attachments': [],\n",
       "   'message_id': 2,\n",
       "   'in_reply_to': None}],\n",
       " 'role_descriptions': ['alex.johnson@denalitx.com: Denali Therapeutics (Sponsor), Clinical Research Associate',\n",
       "  'maria.garcia@denalitx.com: Denali Therapeutics (Sponsor), Clinical Trial Manager',\n",
       "  'david.miller@syneos.com: Syneos Health (CRO), Clinical Research Associate',\n",
       "  'schen@ucsfmed.org: UCSF Medical Center (Site), Clinical Research Coordinator',\n",
       "  'mlee@ucsfmed.org: UCSF Medical Center (Site), Principal Investigator'],\n",
       " 'description': 'A back-and-forth conversation with a site regarding a participant in Part B who is nearing the end of the 25-week treatment period and has questions about rolling over into the Open-Label Extension (Part C). The site is asking for clarification on the visit schedule and procedures in the OLE to properly consent the participant.'}"
      ]
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "threads = []\n",
    "output_dir = Path(\"generated_email_threads_2\")\n",
    "output_dir.mkdir(exist_ok=True, parents=True)\n",
    "\n",
    "for idx, description in enumerate(email_descriptions):\n",
    "    print(\"Generating email thread for description: \", description)\n",
    "\n",
    "    email_thread_predict = dspy.Predict(DraftSyntheticEmailThread)\n",
    "    email_thread_result = email_thread_predict(\n",
    "        email_description=description, name=NAME, role=ROLE, organization=ORGANIZATION\n",
    "    )\n",
    "\n",
    "    emails_data = [\n",
    "        {\n",
    "            \"from_address\": email.from_address,\n",
    "            \"to_addresses\": email.to_addresses,\n",
    "            \"cc_addresses\": email.cc_addresses,\n",
    "            \"subject\": email.subject,\n",
    "            \"timestamp\": email.timestamp,\n",
    "            \"body\": email.body,\n",
    "            \"attachments\": email.attachments,\n",
    "            \"message_id\": email.message_id,\n",
    "            \"in_reply_to\": email.in_reply_to,\n",
    "        }\n",
    "        for email in email_thread_result.email_thread\n",
    "    ]\n",
    "\n",
    "    thread_data = {\n",
    "        \"emails\": emails_data,\n",
    "        \"role_descriptions\": email_thread_result.role_descriptions,\n",
    "        \"description\": description,\n",
    "    }\n",
    "    threads.append(thread_data)\n",
    "\n",
    "    thread_file = output_dir / f\"thread_{idx:03d}.json\"\n",
    "    with open(thread_file, \"w\") as f:\n",
    "        json.dump(thread_data, f, indent=2)\n",
    "    print(f\"Saved thread {idx} to {thread_file}\")\n",
    "\n",
    "summary_file = output_dir / \"all_threads.json\"\n",
    "with open(summary_file, \"w\") as f:\n",
    "    json.dump({\"study_overview\": STUDY_OVERVIEW, \"role\": ROLE, \"threads\": threads}, f, indent=2)\n",
    "print(f\"Saved summary to {summary_file}\")\n",
    "\n",
    "thread_data"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "birdhouse_backend_env",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.10"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
